U.S. India Business Council (USIBC) in a submission to U.S. Trade Representatives (USTR) for the 2016 Special 301 Review has clearly stated “the Government of India has privately reassured it would not use Compulsory Licenses (CL) for commercial purposes.”; indicating that India’s patent office will be restrictive in granting licenses to domestic players to produce cheaper versions of patented drugs. USIBC has also said that they were “encouraged by the way things are trending” in the developments related to the Intellectual Property Rights (IPR) policy in the last one year in India.
Submissions to USTR for the 2016 Special 301 Review made by at least four industry bodies, the US Chamber of Commerce, Pharmaceutical Research and Manufacturers of America (PhRMA), USIBC and Alliance for Fair Trade with India (AFTI) said that a “positive” approach has been developed by the India government in regard to compulsory licensing.
Read full submission:
US Chamber of Commerce’s Global Intellectual Property Centre
US- India Business Council